[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-i-uterine-corpus-carcinoma-or-carcinosarcoma-ajcc-v8\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-i-uterine-corpus-carcinoma-or-carcinosarcoma-ajcc-v8":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100488915","phase-3-impact-of-sentinel-lymph-node-mapping-on-patient-reported-lower-extremity-limb-dysfunction-in-stage-i-endometrial-cancer-100488915",false,"NCT05646316","Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer","A Phase III Trial Of The Impact Of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction In Endometrial Cancer","Inclusion Criteria:\n\n* Histologically proven diagnosis of endometrial cancer based on endometrial sampling with a plan to undergo laparoscopic or robotic hysterectomy and lymphatic assessment as part of primary management. Biopsy must be performed within 90 days prior to registration\n* Clinical stage I endometrial cancer based on the following diagnostic workup:\n\n  * History\u002Fphysical examination within 30 days prior to registration is reassuring for the absence of metastatic disease\n* Age \\>= 18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information\n* Patients must speak English, Spanish, or Korean\n\nExclusion Criteria:\n\n* Patients whom the surgeon believes is not a candidate for pelvic lymphadenectomy due to medical comorbidities or other technical challenges (i.e. morbid obesity or prior surgery)\n* History of chemotherapy or immunotherapy for the treatment of endometrial cancer. Progestin-containing therapies such as megestrol, medroxyprogesterone, or levonorgestrel-containing intrauterine device (IUD) are acceptable\n* History of radiation to the pelvis, groin or lower extremities, or surgery to the pelvic lymph nodes or inguinal lymph nodes\n* Patients who are going to undergo another elective surgery during the same operative event as their hysterectomy (i.e., sacrocolpopexy, cholecystectomy)\n* Patients with severe, active co-morbidity defined as follows:\n\n  * History of patient or provider identified lower extremity lymphedema\n  * History of patient or provider identified chronic lower extremity swelling\n  * History of lower extremity or pelvic deep venous thromboembolism within 90 days of registration\n  * History of lower extremity cellulitis within 90 days of registration","FEMALE","18 Years",{"count":19,"type":20},428,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Standard lymph node dissection removes lymph nodes around the uterus during a hysterectomy to look for spread of cancer from the uterus to nearby lymph nodes. Sentinel lymph node mapping uses a special dye and camera to look for cancer that may have spread to nearby lymph nodes. Comparing the results of the procedures may help doctors predict the risk of long-term swelling in the legs.",[26],"Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","RECRUITING","2026-08-05",{"date":30,"type":31},"2026-08-07","ACTUAL",{"date":33,"type":31},"2022-12-07",{"date":35,"type":20},"2026-10-31",{"name":37,"class":38},"NRG Oncology","OTHER",60,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100648516","web-based-lifestyle-program-mhealth-and-ema-intervention-to-improve-weight-loss-in-rural-stage-i-iii-postmenopausal-breast-and-endometrial-cancer-survivors-hero-c-trial-100648516","NCT07723235","Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial","Health Engagement for Rural Ohio Cancer Survivors (HERO-C)","Inclusion Criteria:\n\n* Body mass index (BMI) ≥ 25kg\u002Fm\\^2\n* Age: 40-69 years\n* 1-5 years post-diagnosis of stage I-III postmenopausal breast cancer or stage I-III endometrial cancer\n* No known evidence of recurrence (local or distant) or second, primary cancer\n* No prior history of new other malignancy since their breast or endometrial cancer diagnosis (other than non-melanoma skin cancer)\n* Not currently participating in any weight loss programs, no personal trainer, and not meeting the physical activity guidelines\n* No use of any anti-obesity medications in the last 6 months and no plan to start anti-obesity medications during the study period\n* The ability to walk two blocks without a walker or cane\n* The ability to speak and read English\n* Have access to internet with a computer, tablet, or smart phone\n* Live in rural counties in Ohio and not planning to move away during the study\n* Are not pregnant, breastfeeding or less than 12-month post-partum and do not plan to become pregnant during the study\n\nExclusion Criteria:\n\n* Severe medical conditions, such as unstable cardiovascular disease or digestive disorders, that would preclude physical activity and dietary intervention\n* Lack of physician clearance if determined necessary by the Physical Activity Readiness Questionnaire (PAR-Q+)\n* Acute physical limitations for unsupervised exercises at home\n* Unable to give informed consent","40 Years","69 Years",{"count":50,"type":20},90,[52],"NA","This clinical trial identifies the needs and preferences of rural stage I-III postmenopausal breast and endometrial cancer survivors and evaluates the impact of an adaptive, online program, mobile (m)Health + ecological momentary assessment (EMA) intervention, on lifestyle modification and their weight loss efforts. Obesity, a condition marked by an abnormally high, unhealthy amount of body fat, is associated with lower physical and psychological well-being, higher risk of recurrence, and higher cancer-specific and all-cause mortality (number of deaths). Lifestyle factors, such as low physical activity and unhealthy diet, are the main contributors to obesity that are modifiable. Lifestyle weight loss programs focusing on modifiable factors can improve cancer-specific survival and many aspects of health, but access to these programs can be challenging in rural settings. A remote lifestyle program, adapted to individual goals and needs, may help promote healthy behaviors, improve cancer outcomes, and reduce disease burden in stage I-III postmenopausal breast and endometrial cancer survivors.",[55,56,57,58,26,59,60],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Endometrial Carcinoma","Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8","NOT_YET_RECRUITING","2026-07-20",{"date":64,"type":31},"2026-07-23",{"date":66,"type":20},"2026-10-10",{"date":68,"type":20},"2027-12-31",{"name":70,"class":38},"Ohio State University Comprehensive Cancer Center",1]